Global Leukocyte Reduction Filter Market By Type (Whole Blood, Red Blood Cell (RBC), Platelet, Plasma), By End-Use Category (Bed Side Use {Whole Blood, Red Blood Cell [RBC], Platelet, Plasma}, Laboratory Use {Whole Blood, Red Blood Cell [RBC], Platelet, Plasma}, In-line System {Whole Blood, Red Blood Cell [RBC], Platelet, Plasma}), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)
Market Outlook:
The global Leukocyte Reduction Filter market was valued at USD 4.28 million in 2019 and is projected to reach USD 6.02 million by 2027, expanding at a CAGR of 6.1% during the forecast period. In terms of volume, the market is projected to expand at a CAGR of 5.6% during the forecast period. The human body is responsible for leukocytes, also known as white blood cells, which fights against bacteria, viruses, and irregular cells to prevent diseases or illnesses. However, leukocytes are not well tolerated and associated with certain kinds of transfusion reactions when they are transfused into another human. Leucocytes are separated from the blood before storage to avoid transfusion reactions or diseases. Leukocyte reduction filters are used to lessen complications related to transfused white blood cells that are contained in whole blood, platelets, red blood cells, and plasma.
Market Dynamics
Rising demand for plasma and platelets for several serious therapies is expected to contribute to the market growth. Moreover, factors such as increasing occurrence of leukemia, growing number of blood donations, and growing awareness related to blood donation are anticipated to contribute to the growth of global leukocyte reduction filter market during the forecast period.
The incidence of leukemia varies between pathological types and population. A total of 437.0 thousand new cases were reported and 309.0 thousand cancer deaths were caused due to leukemia worldwide in 2018. According to the American Cancer Society, about 1.32 million individuals were diagnosed with leukemia and lymphoma are reportedly each year. Additionally, according to the National Kidney Foundation, about 10% of the global population is affected by chronic kidney disease. As a result, high prevalence and elevated incidence rates of chronic diseases have increased the demand for blood and blood supplies, which in turn, is projected to increase the demand for leukocyte reduction filter during the forecast period.
The necessity for blood products and blood is growing every year in several nations. In low and middle-income countries, demand exceeds supply, making it is difficult for blood services to make adequate blood accessible, while ensuring its quality and safety. An upsurge of 7.8 million blood donations from volunteer unpaid donors has been reported between 2013 and 2018. Around, 79 countries collect more than 90% of blood supply from voluntary unpaid blood donors; however, 56 countries collect more than 50% of their blood supply from family/replacement donors or paid donors. Based on samples from 1,000 people, the blood donation rate is 31.5 in high-income countries, 15.9 in upper middle-income countries, 6.8 in lower middle-income countries, and 5.0 donations in low-income countries. Over the last decade, the proportion of blood donations from volunteer unpaid donors has increased and 73 countries in the world are now collecting more than 90% of blood supplies from such donors. Hence, increase in blood donations is expected to increase the demand for leukocyte reduction filters during the forecast period.
The high demand for apheresis technique for blood transfusion is expected to hinder the market growth during the forecast period. The apheresis technique is used to enable operators to choose and collect specific components. Donors can donate the blood manually or to donate certain components by apheresis. Apheresis collects blood components, which offers a number of advantages as compared to the entire blood collected manually. Apheresis divides the components; therefore, no further treatment is required for the blood. Thus, the benefits associated with the apheresis technique is anticipated to impede the market growth during the forecast period.
Segmental Outlook
By type, the leukocyte reduction filter market has been segmented into whole blood, red blood cell (RBC), platelet, and plasma. The whole blood segment is anticipated to account for a substantial share of the market during the forecast period; however, the platelets segment is anticipated to expand at significant pace during the forecast period. Major surgeries can lead to the loss of blood; thus requiring the use of whole blood donation. Increasing demand for blood and plasma from the geriatric population across the globe coupled with rising blood and plasma donations worldwide is expected to drive the growth of whole blood segment during the forecast period. Moreover, advancements in blood transfusion and blood testing devices drive the growth of leukocyte reduction filter market.
By end-use category, the leukocyte reduction filter market has been segmented into bed side use, laboratory use, and in-line system. The laboratory use segment is expected to hold a significant market share in 2020 due to a large number of disease screening and blood typing services prior to transfusion therapy. The safety of blood supply through thorough disease screening, while meeting regulatory standards is maintained by these facilities. In these settings, some regular tests performed on the donated blood include Rh-typing, unexpected RBC antibody checking, blood typing, and infectious disease screening.
Regional Outlook
In terms of regions, the global leukocyte reduction filters market is fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for a significant share of the global market in 2019. The market in Asia Pacific is projected to expand at significant CAGR during the forecast period. The rise in the adoption of leukocyte reduction filters in North America is attributed to the increase in the adoption of new technology and growth in disposable revenue. The growth in geriatric population and prevalence of leukemia in this region are driving the demand for leukocyte reduction filters. In 2019, approximately 61,780 individuals were diagnosed with leukemia, according to the Leukemia and Lymphoma Society (LLS). In the US from 2011 to 2015, leukemia was the sixth common cancer claiming the lives of men and women, according to the LLS and the American Cancer Society. Moreover, increasing clinical research activities and high presence of biotech and pharmaceutical companies are fueling the market in the region.
Key Benefits for Industry Participants & Stakeholders
- In-depth Analysis of the Global Leukocyte Reduction Filter Market
- Historical, Current and Projected Market Size in terms of Value and Volume (Mn Units)
- Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
- Industry Drivers, Restraints and Opportunities Covered in the Study
- Recent Industry Trends and Developments
- Competitive Landscape & Strategies of Key Players
- Neutral Perspective on Global Leukocyte Reduction Filter Market Performance
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Leukocyte Reduction Filter Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Leukocyte Reduction Filter Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Leukocyte Reduction Filter Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Leukocyte Reduction Filter Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Leukocyte Reduction Filter Market Size & Forecast, 2017-2027
4.5.1 Leukocyte Reduction Filter Market Size and Y-o-Y Growth
4.5.2 Leukocyte Reduction Filter Market Absolute $ Opportunity
4.6 Pricing Analysis & Forecast, By Type, 2017-2027
4.7 Patent Landscape
4.8 Intellectual Property Trends
4.9 Intellectual Property Strategy Outlook
4.10 New Market Players: Analysis
4.11 Market Entry Opportunities
Chapter 5 Global Leukocyte Reduction Filter Market Analysis and Forecast By Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Type
5.1.2 Basis Point Share (BPS) Analysis By Type
5.1.3 Absolute $ Opportunity Assessment By Type
5.2 Leukocyte Reduction Filter Market Size & Volume Forecast By Type
5.2.1 Whole Blood
5.2.2 Red Blood Cell (RBC)
5.2.3 Platelet
5.2.4 Plasma
5.3 Market Attractiveness Analysis By Type
Chapter 6 Global Leukocyte Reduction Filter Market Analysis and Forecast By End-Use Category
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By End-Use Category
6.1.2 Basis Point Share (BPS) Analysis By End-Use Category
6.1.3 Absolute $ Opportunity Assessment By End-Use Category
6.2 Leukocyte Reduction Filter Market Size & Volume Forecast By End-Use Category
6.2.1 Bed Side Use
6.2.1.1 Whole Blood
6.2.1.2 Red Blood Cell (RBC)
6.2.1.3 Platelet
6.2.1.4 Plasma
6.2.2 Laboratory Use
6.2.2.1 Whole Blood
6.2.2.2 Red Blood Cell (RBC)
6.2.2.3 Platelet
6.2.2.4 Plasma
6.2.3 In-line System
6.2.3.1 Whole Blood
6.2.3.2 Red Blood Cell (RBC)
6.2.3.3 Platelet
6.2.3.4 Plasma
6.3 Market Attractiveness Analysis By End-Use Category
Chapter 7 Global Leukocyte Reduction Filter Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Leukocyte Reduction Filter Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Leukocyte Reduction Filter Analysis and Forecast
9.1 Introduction
9.2 North America Leukocyte Reduction Filter Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Leukocyte Reduction Filter Market Size & Volume Forecast By Type
9.6.1 Whole Blood
9.6.2 Red Blood Cell (RBC)
9.6.3 Platelet
9.6.4 Plasma
9.7 Basis Point Share (BPS) Analysis By Type
9.8 Absolute $ Opportunity Assessment By Type
9.9 Market Attractiveness Analysis By Type
9.10 North America Leukocyte Reduction Filter Market Size & Volume Forecast By End-Use Category
9.10.1 Bed Side Use
9.10.1.1 Whole Blood
9.10.1.2 Red Blood Cell (RBC)
9.10.1.3 Platelet
9.10.1.4 Plasma
9.10.2 Laboratory Use
9.10.2.1 Whole Blood
9.10.2.2 Red Blood Cell (RBC)
9.10.2.3 Platelet
9.10.2.4 Plasma
9.10.3 In-line System
9.10.3.1 Whole Blood
9.10.3.2 Red Blood Cell (RBC)
9.10.3.3 Platelet
9.10.3.4 Plasma
9.11 Basis Point Share (BPS) Analysis By End-Use Category
9.12 Absolute $ Opportunity Assessment By End-Use Category
9.13 Market Attractiveness Analysis By End-Use Category
Chapter 10 Europe Leukocyte Reduction Filter Analysis and Forecast
10.1 Introduction
10.2 Europe Leukocyte Reduction Filter Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Leukocyte Reduction Filter Market Size & Volume Forecast By Type
10.6.1 Whole Blood
10.6.2 Red Blood Cell (RBC)
10.6.3 Platelet
10.6.4 Plasma
10.7 Basis Point Share (BPS) Analysis By Type
10.8 Absolute $ Opportunity Assessment By Type
10.9 Market Attractiveness Analysis By Type
10.10 Europe Leukocyte Reduction Filter Market Size & Volume Forecast By End-Use Category
10.10.1 Bed Side Use
10.10.1.1 Whole Blood
10.10.1.2 Red Blood Cell (RBC)
10.10.1.3 Platelet
10.10.1.4 Plasma
10.10.2 Laboratory Use
10.10.2.1 Whole Blood
10.10.2.2 Red Blood Cell (RBC)
10.10.2.3 Platelet
10.10.2.4 Plasma
10.10.3 In-line System
10.10.3.1 Whole Blood
10.10.3.2 Red Blood Cell (RBC)
10.10.3.3 Platelet
10.10.3.4 Plasma
10.11 Basis Point Share (BPS) Analysis By End-Use Category
10.12 Absolute $ Opportunity Assessment By End-Use Category
10.13 Market Attractiveness Analysis By End-Use Category
Chapter 11 Asia Pacific Leukocyte Reduction Filter Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Leukocyte Reduction Filter Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Leukocyte Reduction Filter Market Size & Volume Forecast By Type
11.6.1 Whole Blood
11.6.2 Red Blood Cell (RBC)
11.6.3 Platelet
11.6.4 Plasma
11.7 Basis Point Share (BPS) Analysis By Type
11.8 Absolute $ Opportunity Assessment By Type
11.9 Market Attractiveness Analysis By Type
11.10 Asia Pacific Leukocyte Reduction Filter Market Size & Volume Forecast By End-Use Category
11.10.1 Bed Side Use
11.10.1.1 Whole Blood
11.10.1.2 Red Blood Cell (RBC)
11.10.1.3 Platelet
11.10.1.4 Plasma
11.10.2 Laboratory Use
11.10.2.1 Whole Blood
11.10.2.2 Red Blood Cell (RBC)
11.10.2.3 Platelet
11.10.2.4 Plasma
11.10.3 In-line System
11.10.3.1 Whole Blood
11.10.3.2 Red Blood Cell (RBC)
11.10.3.3 Platelet
11.10.3.4 Plasma
11.11 Basis Point Share (BPS) Analysis By End-Use Category
11.12 Absolute $ Opportunity Assessment By End-Use Category
11.13 Market Attractiveness Analysis By End-Use Category
Chapter 12 Latin America Leukocyte Reduction Filter Analysis and Forecast
12.1 Introduction
12.2 Latin America Leukocyte Reduction Filter Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Leukocyte Reduction Filter Market Size & Volume Forecast By Type
12.6.1 Whole Blood
12.6.2 Red Blood Cell (RBC)
12.6.3 Platelet
12.6.4 Plasma
12.7 Basis Point Share (BPS) Analysis By Type
12.8 Absolute $ Opportunity Assessment By Type
12.9 Market Attractiveness Analysis By Type
12.10 Latin America Leukocyte Reduction Filter Market Size & Volume Forecast By End-Use Category
12.10.1 Bed Side Use
12.10.1.1 Whole Blood
12.10.1.2 Red Blood Cell (RBC)
12.10.1.3 Platelet
12.10.1.4 Plasma
12.10.2 Laboratory Use
12.10.2.1 Whole Blood
12.10.2.2 Red Blood Cell (RBC)
12.10.2.3 Platelet
12.10.2.4 Plasma
12.10.3 In-line System
12.10.3.1 Whole Blood
12.10.3.2 Red Blood Cell (RBC)
12.10.3.3 Platelet
12.10.3.4 Plasma
12.11 Basis Point Share (BPS) Analysis By End-Use Category
12.12 Absolute $ Opportunity Assessment By End-Use Category
12.13 Market Attractiveness Analysis By End-Use Category
Chapter 13 Middle East & Africa (MEA) Leukocyte Reduction Filter Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Leukocyte Reduction Filter Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Leukocyte Reduction Filter Market Size & Volume Forecast By Type
13.6.1 Whole Blood
13.6.2 Red Blood Cell (RBC)
13.6.3 Platelet
13.6.4 Plasma
13.7 Basis Point Share (BPS) Analysis By Type
13.8 Absolute $ Opportunity Assessment By Type
13.9 Market Attractiveness Analysis By Type
13.10 Middle East & Africa (MEA) Leukocyte Reduction Filter Market Size & Volume Forecast By End-Use Category
13.10.1 Bed Side Use
13.10.1.1 Whole Blood
13.10.1.2 Red Blood Cell (RBC)
13.10.1.3 Platelet
13.10.1.4 Plasma
13.10.2 Laboratory Use
13.10.2.1 Whole Blood
13.10.2.2 Red Blood Cell (RBC)
13.10.2.3 Platelet
13.10.2.4 Plasma
13.10.3 In-line System
13.10.3.1 Whole Blood
13.10.3.2 Red Blood Cell (RBC)
13.10.3.3 Platelet
13.10.3.4 Plasma
13.11 Basis Point Share (BPS) Analysis By End-Use Category
13.12 Absolute $ Opportunity Assessment By End-Use Category
13.13 Market Attractiveness Analysis By End-Use Category
Chapter 14 Competition Landscape
14.1 Leukocyte Reduction Filter Market: Competitive Dashboard
14.2 Global Leukocyte Reduction Filter Market: Market Share Analysis, 2020
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Haemonetics Corporation
14.3.2 TERUMO BCT, INC.
14.3.3 Guangzhou Daji Medical Science and Technology Co., Ltd.
14.3.4 Mitra Industries (P) Ltd.
14.3.5 Kawasumi Laboratories, Inc.
14.3.6 Nanjing Shuangwei Biotechnology Co., Ltd.
14.3.7 PURIBLOOD MEDICAL CO., LTD.
14.3.8 Bıçakcılar
14.3.9 Shandong Zhongbaokang Medical Implements Co., Ltd.
14.3.10 Fresenius Kabi AG
14.3.11 Macopharma
14.3.12 Asahi Kasei Medical Co., Ltd.
14.3.13 NPP Interoko (mediana-tech.ru)
By Type
- Whole Blood
- Red Blood Cell (RBC)
- Platelet
- Plasma
By End-Use Category
- Bed Side Use
- Whole Blood
- Red Blood Cell (RBC)
- Platelet
- Plasma
- Laboratory Use
- Whole Blood
- Red Blood Cell (RBC)
- Platelet
- Plasma
- In-line System
- Whole Blood
- Red Blood Cell (RBC)
- Platelet
- Plasma
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- Italy
- U.K.
- Spain
- Russia
- Rest of the Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- South East Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of Middle East & Africa
Key Market Players Profiled in the Report
- Haemonetics Corporation
- TERUMO BCT, INC.
- Guangzhou Daji Medical Science and Technology Co., Ltd.
- Mitra Industries (P) Ltd.
- Kawasumi Laboratories, Inc.
- Nanjing Shuangwei Biotechnology Co., Ltd.
- PURIBLOOD MEDICAL CO., LTD.
- Bıçakcılar
- Shandong Zhongbaokang Medical Implements Co., Ltd.
- Fresenius Kabi AG
- Macopharma
- Asahi Kasei Medical Co., Ltd.
- NPP Interoko (mediana-tech.ru)
- Key players in the market include Haemonetics Corporation, TERUMO BCT, INC., Asahi Kasei Medical Co., Ltd., Macopharma, and Fresenius Kabi AG among others. These companies are considered as key manufacturers of leukocyte reduction filter based on their revenue, research & development (R&D) activities, regional presence, and supply chain management system.
- The players are adopting key strategies such as merger, acquisition, and geographical expansion in order to strengthen their market position.
- For instance, in May 2019, PURIBLOOD MEDICAL CO., LTD. received TFDA approval for a leukocyte reduction filter for red blood cells. This leukocyte reduction filter is easy to operate and has a high filtration speed.
- In January 2020, Fresenius Kabi AG inaugurated the expansion of its transfusion and apheresis disposables plant in the Dominican Republic. The company invested more than USD 33 million in this expansion.
Our Clients
FAQ Section
Some frequently asked quetions about this report!
Additional company profiles can be provided on request.
Yes, the report covers product specific information such as whole blood, red blood cells (RBCs), platelets, and plasma.
According to the Growth Market Reports report, in terms of value the market leukocyte reduction filter is likely to register a CAGR of 6.1% during forecast period 2020-2027, with an anticipated valuation of USD 6.02 million by the end of the 2027.
The global leukocyte reduction filter market report provides the additional data such as patent landscape, intellectual property trends, intellectual property strategy outlook, new market players analysis, and market entry opportunities. Moreover, the report also provides the company market share analysis, cross splits on regional level and volume data for the global leukocyte reduction filter market.
The market is driven by factors such as increasing occurrence of leukemia, growing number of blood donations, increasing awareness related to blood donation, and rising demand for plasma and platelets for several serious therapies.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
The market is expected to witness a decline of 7.0% in 2020 as compared to 2019 owing to the negative impact of COVID-19.
The base year considered for the global leukocyte reduction filter market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years and the forecast is provided from 2020 to 2027.
Laboratories, hospitals, and blood centers are the key end users driving the market growth.
Major Manufactures include Haemonetics Corporation, TERUMO BCT, INC., Asahi Kasei Medical Co., Ltd., Macopharma, and Fresenius Kabi AG among others.
Related Reports
Some other reports from this category!
